Correction to: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review (Drugs in R&D, (2024), 24, 3, (359-381), 10.1007/s40268-024-00481-7)

Mark T. Reding; Shadan Lalezari; Gili Kenet; Giovanni Di Minno; Jonathan Ducore; Alexander Solms; Anita Shah; Pål André Holme; Lone H. Poulsen; Karina Meijer; Mindy Simpson; Maria Elisa Mancuso

doi:10.1007/s40268-024-00494-2

Correction to: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review (Drugs in R&D, (2024), 24, 3, (359-381), 10.1007/s40268-024-00481-7)

Mark T. Reding, Shadan Lalezari, Gili Kenet, Giovanni Di Minno, Jonathan Ducore, Alexander Solms, Anita Shah, Pål André Holme, Lone H. Poulsen, Karina Meijer, Mindy Simpson, Maria Elisa Mancuso^*

^*Corresponding author for this work

Research output: Contribution to journal › Erratum

Abstract

The graphic abstract was missing from this article and should have appeared as below. (Figure presented.) The original article has been corrected.

Original language	English
Journal	Drugs in R and D
DOIs	https://doi.org/10.1007/s40268-024-00494-2
Publication status	E-pub ahead of print - 20-Dec-2024

Access to Document

10.1007/s40268-024-00494-2Licence: CC BY-NC

Handle.net

Persistent link

Fingerprint

Dive into the research topics of 'Correction to: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review (Drugs in R&D, (2024), 24, 3, (359-381), 10.1007/s40268-024-00481-7)'. Together they form a unique fingerprint.

1 Review article

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review
Reding, M. T., Lalezari, S., Kenet, G., Di Minno, G., Ducore, J., Solms, A., Shah, A., Holme, P. A., Poulsen, L. H., Meijer, K., Simpson, M. & Mancuso, M. E., Sept-2024, In: Drugs in R and D. 24, 3, p. 359-381 23 p.
Research output: Contribution to journal › Review article › peer-review

Open Access
File
2 Citations (Scopus)

76 Downloads (Pure)

Cite this

Reding, M. T., Lalezari, S., Kenet, G., Di Minno, G., Ducore, J., Solms, A., Shah, A., Holme, P. A., Poulsen, L. H., Meijer, K., Simpson, M., & Mancuso, M. E. (2024). Correction to: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review (Drugs in R&D, (2024), 24, 3, (359-381), 10.1007/s40268-024-00481-7). Drugs in R and D. Advance online publication. https://doi.org/10.1007/s40268-024-00494-2

@article{f4f730cf851b4a1d855e507dcf7627af,

title = "Correction to: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review (Drugs in R&D, (2024), 24, 3, (359-381), 10.1007/s40268-024-00481-7)",

abstract = "The graphic abstract was missing from this article and should have appeared as below. (Figure presented.) The original article has been corrected.",

author = "Reding, {Mark T.} and Shadan Lalezari and Gili Kenet and {Di Minno}, Giovanni and Jonathan Ducore and Alexander Solms and Anita Shah and Holme, {P{\aa}l Andr{\'e}} and Poulsen, {Lone H.} and Karina Meijer and Mindy Simpson and Mancuso, {Maria Elisa}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = dec,

day = "20",

doi = "10.1007/s40268-024-00494-2",

language = "English",

journal = "Drugs in R and D",

issn = "1174-5886",

publisher = "Springer",

}

Reding, MT, Lalezari, S, Kenet, G, Di Minno, G, Ducore, J, Solms, A, Shah, A, Holme, PA, Poulsen, LH, Meijer, K, Simpson, M & Mancuso, ME 2024, 'Correction to: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review (Drugs in R&D, (2024), 24, 3, (359-381), 10.1007/s40268-024-00481-7)', Drugs in R and D. https://doi.org/10.1007/s40268-024-00494-2

Correction to: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review (Drugs in R&D, (2024), 24, 3, (359-381), 10.1007/s40268-024-00481-7). / Reding, Mark T.; Lalezari, Shadan; Kenet, Gili et al.
In: Drugs in R and D, 20.12.2024.

Research output: Contribution to journal › Erratum

TY - JOUR

T1 - Correction to

T2 - Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review (Drugs in R&D, (2024), 24, 3, (359-381), 10.1007/s40268-024-00481-7)

AU - Reding, Mark T.

AU - Lalezari, Shadan

AU - Kenet, Gili

AU - Di Minno, Giovanni

AU - Ducore, Jonathan

AU - Solms, Alexander

AU - Shah, Anita

AU - Holme, Pål André

AU - Poulsen, Lone H.

AU - Meijer, Karina

AU - Simpson, Mindy

AU - Mancuso, Maria Elisa

PY - 2024/12/20

Y1 - 2024/12/20

N2 - The graphic abstract was missing from this article and should have appeared as below. (Figure presented.) The original article has been corrected.

AB - The graphic abstract was missing from this article and should have appeared as below. (Figure presented.) The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85212686775&partnerID=8YFLogxK

U2 - 10.1007/s40268-024-00494-2

DO - 10.1007/s40268-024-00494-2

M3 - Erratum

AN - SCOPUS:85212686775

SN - 1174-5886

JO - Drugs in R and D

JF - Drugs in R and D

ER -

Reding MT, Lalezari S, Kenet G, Di Minno G, Ducore J, Solms A et al. Correction to: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review (Drugs in R&D, (2024), 24, 3, (359-381), 10.1007/s40268-024-00481-7). Drugs in R and D. 2024 Dec 20. Epub 2024 Dec 20. doi: 10.1007/s40268-024-00494-2

Correction to: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review (Drugs in R&D, (2024), 24, 3, (359-381), 10.1007/s40268-024-00481-7)

Abstract

Access to Document

Handle.net

Other files and links

Fingerprint

Research output

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review

Cite this